Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Prognostic Test for Assessment of Chronic Kidney Disease Progression
Key claim: The FDA is classifying prognostic tests for assessment of chronic kidney disease progression as class II medical devices subject to special controls to assure safety and effectiveness while reducing regulatory burden.
Abstract
(Rule · Health and Human Services Department, Food and Drug Administration) The Food and Drug Administration (FDA) is classifying the prognostic test for assessment of chronic kidney disease progression into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the prognostic test for assessment of chronic kidney disease progression. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients’ access to beneficial innovative devices, in part by reducing regulatory burdens.
Why this matters
Class II classification with special controls creates a clearer 510(k) pathway for CKD progression prognostic tests, potentially expanding availability of risk-stratification tools that guide nephrology referrals and treatment intensity. For patients and providers managing kidney disease, standardized regulatory criteria may shape which tests reach market and how insurers evaluate coverage.